Madrigal Pharmaceuticals (MDGL) vs Protagonist Therapeutics (PTGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Protagonist Therapeutics (PTGX) has outperformed Madrigal Pharmaceuticals (MDGL) over the past year, gaining 114.3% versus a gain of 11.8%. Over five years, MDGL leads with a +466.0% price change compared with +351.8% for PTGX. Madrigal Pharmaceuticals is the larger company by market cap ($11.02 billion vs $9.05 billion), about 1.2 times the size.
Madrigal Pharmaceuticals converts more of its revenue into profit, with a net margin of -30.1% versus -282.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MDGL | PTGX |
|---|---|---|
| Share price | $476.91 | $139.91 |
| Market cap | $11.02B | $9.05B |
| 1-day change | -2.22% | -0.72% |
| YTD return | -16.25% | +60.19% |
| 1-year return | +11.79% | +114.26% |
| 5-year return | +466.00% | +351.76% |
| P/E ratio (TTM) | — | 135.83 |
| Forward P/E | 49.55 | — |
| EPS (TTM) | $-12.85 | $1.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $958.40M | $46.02M |
| Revenue growth (YoY) | +432.05% | -89.41% |
| Net income (latest FY) | $-288.28M | $-130.15M |
| Operating margin | -31.31% | -343.63% |
| Net margin | -30.08% | -282.83% |
| 52-week high | $615.00 | $160.81 |
| 52-week low | $393.61 | $65.56 |
| Distance from 52-week high | -22.45% | -13.00% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +43.03% | +24.86% |
| Average volume | 289.31K | 632.64K |
| Shares outstanding | 23.10M | 64.71M |
| Employees | 915 | 141 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PTGX has outperformed MDGL by 102.5 percentage points over the past year.
- Madrigal Pharmaceuticals is more profitable, keeping -30.1 cents of every revenue dollar as net income versus -282.8 cents for Protagonist Therapeutics.
- Madrigal Pharmaceuticals grew revenue faster in its latest fiscal year (+432.05% vs -89.41%).
About Madrigal Pharmaceuticals
MDGL stock →Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH.
Health Care · Biotechnology: Pharmaceutical Preparations · 915 employees
About Protagonist Therapeutics
PTGX stock →Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 141 employees
MDGL vs PTGX FAQ
Which is bigger, Madrigal Pharmaceuticals or Protagonist Therapeutics?
Madrigal Pharmaceuticals (MDGL) is larger, with a market capitalization of $11.02B compared with $9.05B for Protagonist Therapeutics (PTGX).
Which stock has performed better over the past year, MDGL or PTGX?
PTGX returned +114.26% over the past 12 months, compared with +11.79% for MDGL (price return, excluding dividends). Past performance does not predict future results.
Are Madrigal Pharmaceuticals and Protagonist Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.